Breakthrough in Colorectal Cancer Treatment: Pre-Surgical Immunotherapy Yields Sustained Remission A groundbreaking clinical trial, NEOPRISM-CRC, led by researchers at University College London (UCL) and University College London Hospitals (UCLH), has demonstrated remarkable efficacy of pre-surgical immunotherapy in patients with stage II or III MMR-deficient/MSI-high colorectal cancer. This genetic subtype, accounting for 10-15% of non-metastatic.

A recent study published in Genes & Development reveals that the MYC oncoprotein, long known to drive tumor proliferation and metabolism, also plays a direct role in DNA repair. In work led by researchers at Oregon Health & Science University, a modified form of MYC was shown to localize to sites of chemotherapy- or replication-induced…